CD8A and neoplasm: found the limitations of TMB as a predictor of anti‐PD1 immunotherapy response in CRC, and anti‐PD1 drugs release PD1‐PDL1 interactions between CD8+ T cells and macrophages, thereby promoting cytotoxic anti‐tumor activity.34